expression. 15, 18 This raises the possibility that failure of a com-
petitive inhibitor of P-gp to completely sensitize the tumor to chemotherapeutic agents may contribute to the generation of a more resistant cancer cell. The use of antisense to directly Introduction inhibit MDR1 gene expression is therefore an attractive alternative to reverse MDR1-mediated drug resistance. The use of chemotherapeutic agents offers effective treatment
In this study, we have investigated the use of antisense olifor a variety of malignancies. The primary limitation to the gonucleotides to reverse drug resistance in CCRF-CEM human utility of these agents is the appearance of drug-resistant canleukemia cells selected for resistance by treatment with vincer cells.
1-3 Overexpression of the MDR1 gene has been cristine. These cells have been characterized previously directly implicated in resistance to a broad spectrum of and exhibit the classic multidrug-resistant phenotype chemotherapeutic agents including the anthracyclines, epipoaccompanied by increased expression of MDR1. 19 The purdophylotoxins and vinca alkaloids. 4 For some types of cancer, pose of this study was to characterize antisense oligonucleoespecially hematological malignancies, evidence has accumutide inhibition of MDR1 in drug-resistant lymphoblastic cells lated indicating that MDR1 expression may be the predomiand determine if it might offer advantages over classical P-gp nant factor in preventing the efficacy of chemotherapeutic inhibitors. We show that MDR1 targeted antisense partially agents. 5, 6 Many cell culture systems designed to model the reverses resistance in drug-resistant cells and lessens the generation of drug-resistant malignancies in the clinic have induction of MDR1 associated with exposure to the chemosimilarly demonstrated that overexpression of MDR1 after therapeutic agent daunorubicin, or the P-gp antagonist treatment with chemotherapeutic agents parallels resistance to cyclosporin. the same agents which become ineffective in the clinic. 7 Introduction of the MDR1 gene into drug sensitive cells 8 or into mice to produce transgenic animals 9 similarly confers resistMaterials and methods ance to the agents described above. The MDR1 gene encodes a membrane-bound glycoprotein (P-glycoprotein (P-gp)),
Reagents
which has been shown to transport a variety of chemotherapeutic drugs out of the cell in an energy-dependent process. 4 Daunorubicin, vincristine, verapamil, 3-(4,5-dimethylthiazolIn short, cell culture, animal and clinical studies strongly sug-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and DMSO gest that overexpression of the MDR1 gene may be the single were purchased from Sigma Chemical Co (St Louis, MO, USA 
Cell culture
PBS and the fluorescence analyzed on a Coulter Epics XL flow cytometer (Coulter, Hialeah, FL, USA) at 488 nm with a The generation and characterization of drug-resistant CCRF-CEM leukemia cells has been described previously. 19 The cells 525 nm band pass filter. are routinely grown in RPMI-1640 media supplemented with 10% fetal calf serum (Hyclone, Salt Lake City, UT, USA) and maintained at 37°C in a humidified atmosphere of 5%
Ribonuclease protection assay CO 2 /95% air.
MDR1 mRNA was detected in CEM60VCR cells using a ribonuclease protection assay with a uniformly labeled T3 antisense RNA probe (507 nucleotides) covering exons 5 to 8 of
Treatment with oligonucleotides
the human MDR1 mRNA. The probe was obtained by rtPCR (Perkin Elmer, Foster City, CA, USA) using primers: (1) 5′-The antisense sequences used were: 1729, 5′-TCT TTG CTC CTC CAT TGC GGT CCC C-3′, (sequence information AAC CAG CAC CCC AGC ACC-3′; and (2) 5′-GCG GCT CTT CCA AGC TCA-3′) on RNA isolated from drug-resistant provided by Larry Smith, University of Nebraska); 1786, reversed control of 1729, 5′CCC CTG GCG TTA CCT CCT CG colon cancer cells (LoVo 350-1, developed in this laboratory). The sequence of the fragment was confirmed by dideoxy T TTC T-3′; 474, 5′-CCC GAC CTC GCG CTC CTT GG-3′; 1795, A DNA-RNA hybrid of this sequence, 5′CCC GAC CTC sequencing and it was subcloned into a TA cloning vector (Invitrogen, San Diego, CA, USA). An EcoRI fragment was then GCG CTC CUU GG-3′ (bold characters indicate bases linked to 2′-O-methyl modified sugars); 1796, a scrambled control cloned into pBluscript II SK +/− (Stratagene, La Jolla, CA, USA). Total cellular RNA (15 g) was isolated using TriZOL hybrid oligonucleotide, 5′-ACU CGC CTC CCA CGT AGT GC U U-3′; and 1962, a reverse control hybrid olignucleotide for (Gibco BRL), hybridized with 8 × 10 4 c.p.m. of probe followed by ribonuclease digestion performed as described by the 1795, 5′-GGU UCC TCG CGC TCC AGC CC-3. For antisense experiments, cells were treated for 4 days in the presence of manufacturer (Ambion, Austin, TX, USA). The reactions were run on a 4% denaturing gel and the bands quantified using a phosphorothioate oligonucleotide. At the beginning of cell treatment, cells were treated with a combination of oligonuPhosphorimager (BioRad, Hercules, CA, USA). Normalization for the amount of RNA was conducted by simultaneously percleotide and lipofectin to facilitate oligonucleotide uptake. Briefly, cells were seeded at low density (0.1 × 10 6 cells/ml forming a ribonuclease protection using the ribosomal associated probe 36B4.
20
RPMI-1640 media without serum and antibiotic-free) into a T75 tissue culture flask. The lipofectin/oligonucleotide mixture was prepared by mixing 100 l of oligonucleotide with 100 l of lipofectin and allowing incubation at room tempera-
P-glycoprotein function
ture for 15 min. The amounts of lipofectin and oligonucleotide were adjusted to give a final concentration of 2.5 g/ml lipoCharacterization of P-gp function was determined by R123 retention. After treatment with oligonucleotides, cells were fectin in culture media and the desired concentration of oligonucleotide when added to cells. After 4 h incubation at first centrifuged out of medium containing oligonucleotide and resuspended in a minimal volume (0.5 ml) of complete 37°C, sufficient fetal calf serum was added to give a final concentration of 5% in the cell culture medium. After 3 days incumedium. An equal volume of complete medium containing 1 g/ml R123 was then added. At given time-points, cells bation, an additional 1 ml of complete medium containing oligonucleotide was added to cells. The following day cells were were analyzed by FCM for R123-associated fluorescence. analyzed for MDR1 expression by staining with MRK16, rhodamine-123 (R123) retention and/or sensitivity to vincristine.
Uptake of oligonucleotides was determined by incubating
Determination of cytotoxicity using the tetrazolium dye assay cells with fluoroscein-conjugated forms of the oligonucleotides 1729, 474, 1795, and 1786 followed by FCM analysis and/or confocal microscopy.
This procedure was modified slightly for antisense treatment from Eliason et al. 21 CEM60VCR cells were treated with oligonucleotides as described above and then seeded at 10 000 cells per well in 96 well plates using RPMI 1640 media sup-
Expression of P-glycoprotein
plemented with 10% fetal bovine serum. Vincristine was added at the indicated concentrations and the cells were incuDetermination of P-gp expression was performed by staining with the MRK16 monoclonal antibody. The analysis was conbated for 4 days. Cytotoxicity was assayed by quantitating the metabolism of MTT. Briefly, 50 l of a 2 mg/ml stock of MTT ducted by a modification of the procedure of Ivy et al. 19 Briefly, 0.5 × 10 6 cells were washed once with Hank's balwas added to each well and incubated for 2 h. The media was the aspirated and the blue formazan crystals dissolved by the anced salt solution containing 0.5% bovine serum albumin and 0.1% sodium azide (washing solution) and Fc receptors addition of 100 l of DMSO (Sigma). The OD was read on a Ceres 900 Hdi plate reader (Biotek Instruments Inc, Winooski, blocked by the addition of 0.15% human IgG at room tem-VT, USA) at 570 nm subtracting 620 nm for background. The data are expressed as percent absorbance relative to that of cells which were not treated with vincristine.
Results

Antisense inhibition of P-glycoprotein expression in CEM60VCR cells
In a previous study, a number of antisense sequences targeted to MDR1 were screened for activity in NIH3T3 cells expressing the cloned human MDR1 gene as well as in drug-resistant human colon cancer cells. 22 The most active of the sequences were one targeted simultaneously to both mRNA regions encoding the ATP-binding site and one targeting the mRNA just 5′ of the AUG translation start site. The latter sequence has been reported previously to inhibit MDR1 gene expression in drug-resistant human colon cancer cells. 23 For the current study we used antisense sequences targeted near the translation start codon. The first is targeted to a region 12 to 36 bases inside the coding region (1729) and the second is targeted to the last 20 bases of the 5′-untranslated region prior to the translation start codon (474). This latter sequence was examined both as a simple phosphorothioate and as a hybrid sequence containing four 2′-O-methyl modified sugars at the 5′ and 3′ ends of the sequence which otherwise possessed a phosphorothioate-modified backbone. Inhibition of expression of the MDR1 gene product was determined by staining with the monoclonal antibody MRK16 followed by FCM analysis. Representative histograms are shown in FCM analysis of MRK16 stained CEM 60VCR cells (Table 1) phorothioate sequence. Staining of cells with the IgG2A isotype control was not inhibited in cells treated with oligonucleotides (data not shown). Dose-dependent inhibition of MRK16 staining was observed down to 0.2 M using all three antisense sequences (Figure 2) . Further, inhibition of MDR1 were treated for 4 days with 1 M of the hybrid antisense sequence (1795) or the reverse control sequence (1962) or left untreated. RNA was extracted and RNase protection performed using one probe for were transferred to oligonucleotide-free medium and incu-MDR1 and another for the ribosomal-associated protein 36B4.
bated for an additional 6 days. Cells were analyzed for P-gp expression immediately after the 4 day treatment was well as at 1, 3 and 6 days after incubation in oligonucleotide-free medium. Compared to untreated cells or cells treated with a reverse control oligonucleotide, the level of inhibition ranged treatment of cells with a control oligonucleotide sequence. from 28 to 46% immediately after treatment (depending on antisense sequence) and 20 to 34% 3 days after the termin-R123 retention in control and antisense treated cells was also ation of treatment (Figure 4) . By 6 days, the levels of P-gp in determined in the presence of 20 M verapamil. This concenall antisense treated cells were comparable to the levels tration of verapamil is sufficient to inhibit most of the P-gp observed in control and untreated cells. To obtain information function even in highly drug-resistant cells. 27 Verapamil on the intracellular presence of oligonucleotides during the increased R123 retention by approximately 50% in both after treatment, each of the oligonucleotides was resyntheuntreated cells and cells treated with a control phosphorothiosized with the addition of a fluorescene group to the 3′ end ate oligonucleotide (data not shown). As expected, however, of the sequence. Cell-associated fluorescence was then meas-R123 retention in verapamil-treated cells was not further ured directly using FCM analysis at the same time-points used increased by pre-treatment with antisense. previously to determine MRK16 staining (Figure 4b ). SignifiTo determine whether the levels of antisense inhibition of cant levels of fluorescence were present in cells up to 3 days MDR1 gene expression (as demonstrated by decreased after all oligonucleotides were removed from the medium.
MRK16 staining and increased R123 retention) was sufficient to reverse the drug-resistant phenotype, CEM60VCR cells were treated with antisense or control oligonucleotides fol-
Inhibition of the multidrug-resistant phenotype
lowed by culturing in the presence of increasing concentrations of vincristine ( Figure 6 ). Cytotoxicity was determined To assess the functional significance of antisense inhibition of by metabolism of the tetrazolium dye MTT. While sensitivity MDR1 gene expression in CEM60VCR cells, retention of the was not restored to that of parental cells, antisense-treated P-gp substrate rhodamine 123 (R123) was determined in both drug-resistant cells exhibited significantly greater sensitivity antisense and control treated cells ( Figure 5 ). It has been to vincristine than either untreated cells or cells treated with shown that correlating R123 efflux with P-gp efflux with Pthe control oligonucleotide. This sensitization is apparent from gp expression is important in establishing the drug-resistant a reduction of the shoulder in the dose-response curve, with phenotype. 26 An increase in R123 retention, indicated by an the slopes in the linear portion being comparable. The LD 50 increase in the ratio of R123 plus oligo over R123 alone, was in antisense-treated CEM60VCR cells is almost three-fold less observed after treatment of cells with antisense concentrations than in untreated cells (50 vs 130 ng/ml). down to 0.2 M. The retention of R123 was not influenced by Increase in rhodamine 123 retention in cells treated with antisense in the presence (solid bars) and absence (hashed bars) of 10 g/ml verapamil. Cells were treated with antisense as described in Figure 1 . Rhodamine 123-associated fluorescence was determined by FCM analysis. ment, cells were transferred to medium free of oligonucleotides and resuspended in either drug-free medium or medium containing 0.5 g/ml daunorubicin or 0.1 M cyclosporin for 24 h. Cells that had been pre-treated with antisense prior to stimulation with daunorubicin still had levels of P-gp well below levels in untreated control cells. Specifically, cells treated with antisense and daunorubicin had approximately 50% of the level of P-gp as was observed in cells treated with chemotherapeutic drugs. 1 The strongest evidence for the clinical relevance of MDR1 expression is derived from patients with hematological malignancies.
3, 28 Recently, the functional
Drug-induced MDR1 expression and inhibition with antisense
significance of P-gp expression has been demonstrated in a study of 120 cases of childhood leukemias. 19 While a variety of chemical inhibitors of P-gp have been identified, the tox-A number of studies have shown that MDR1 expression can be stimulated by a variety of factors including chemotheraicity of these agents (unrelated to P-gp inhibition) has hampered their success in the clinic. A novel approach to inhipeutic agents as well as inhibitors of P-gp function. [13] [14] [15] 18 We determined initially whether these agents could increase bition of P-gp is the use of antisense technology, a valuable tool for inhibiting the expression of specific genes and of MDR1 expression in CEM60VCR cells. Treatment of cells for 24 h with daunorubicin, vincristine, verapamil or cyclosporin potential therapeutic benefit in the clinic. 29 We have employed antisense oligonucleotides both to evaluate the caused a 25 to 75% increase in MRK16 staining (Table 2) .
To assess the potential of antisense to inhibit MDR1 inducimportance of MDR1 expression in drug-resistant leukemia cells and to assess the potential for using MDR1 antisense in tion, cells were pretreated for 4 days with oligonucleotides before stimulation. At the termination of oligonucleotide treata clinical setting. A few previous studies have similarly demonstrated reversal of resistance to chemotherapeutic agents in cultured cells gene. 22 It has recently been shown that phosphorothioate oligonucleotides containing 2′-O-methylribonucleotides at the 5′ This modification also allows for increased binding affinity at the ends of the antisense sequence while retaining the ability to activate RNase H at the middle portion of the oligonucleoWe show that antisense oligonucleotides targeted to the MDR1 gene decrease expression of P-gp, increase retention tide. It was therefore of interest that a 2′-O-methyl hybrid version of the same antisense sequence was a more potent inhibiof rhodamine 123 and sensitize drug-resistant human leukemia cells (CEM60VCR) to the chemotherapeutic agent vincristor of MDR1 expression than was the sequence lacking 2′-Omethyl modifications (Table 1 and Figures 1 to 4) . tine. These cells are of interest as they were derived from cells selected for low levels of MDR1 expression and drug resist-
The majority of studies on the reversal of the multidrug resistance have employed agents which competitively inhibit ance that are closer to levels of resistance observed in clinical samples. 19 This is in contrast to the majority of MDR1 model the function of P-gp such as the calcium channel blocker verapamil and the immunosuppressive agent cyclosporin. While systems which employ cells with much higher levels of drug resistance. The coincident and sequence-dependent inhibition some of these agents are potent inhibitors of P-gp function, we show that treatment of CEM60VCR cells with either veraof the MDR1 gene product, function, and cellular phenotype Suppression of cyclosporin-induced MDR1 expression with antisense. After a 4 day treatment with 1 M oligonucleotide cells were treated for 24 h with 0.12 g/ml cyclosporin (hashed bars). FCM analysis was performed after MRK16 staining.
pamil or cyclosporin, in addition to the chemotherapeutic three-fold) similarly might be expected to be observed in the clinic. We postulate that this level of sensitization would be agents vincristine and daunorubicin, causes an increase in staining with the monoclonal antibody MRK16, suggesting sufficient to show an improvement in the therapeutic index. Further, while it is currently unclear how drug resistant cells that MDR1 gene expression is stimulated. The induction of MDR1 gene expression by daunorubicin in drug-resistant are generated in vivo, the ease with which MDR1 expression can be induced by chemotherapeutic agents and P-gp anta-CCRF-CEM leukemia cells similar to the cells used here has recently been characterized. 14 Increased expression of P-gp gonists, 14, 15 (see also Table 2 ) indicates that MDR1 induction may play a significant role. The ability of antisense to prevent after cyclosporin or verapamil treatment has been reported previously in drug-resistant human tumor lines, although the MDR1 induction as well as to sensitize drug-resistant cells suggests that antisense agents targeted to MDR1 may have mechanism for this is unclear. 15, 18 These observations have caused some concern in the design of clinical trials using utility in the clinic both as sensitizing agents (alone or in combination with a functional P-gp inhibitor) and as prophylatic classical multidrug reversal agents. Specifically, they demonstrate the critical importance of timing in the administration agents during initial chemotherapy to prevent the emergence of MDR1-expressing cells. of a resistance reversal agent (relative to the chemotherapeutic agent) and suggest that these reversal agents may indeed contribute to the emergence of drug resistance should subsequent treatment with chemotherapeutic agents not be 100% effec
